Tandem Diabetes Care
TNDM
78 hedge funds and large institutions have $136M invested in Tandem Diabetes Care in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 20 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
13% less funds holding
Funds holding: 90 → 78 (-12)
18% less capital invested
Capital invested by funds: $165M → $136M (-$28.9M)
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $120K
Top Buyers
Top Sellers
TNDM Hedge Fund Activity: Q2 2016 in Review
78 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q2 2016, worth a combined $136M — down 18% from $165M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of TNDM and 10 opened new positions — a net loss of 10 holders — while 25 trimmed existing stakes and 35 added.
The largest buyer was Archon Capital Management, opening a new position worth an estimated $2.41M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $2.34M sold.
- 78 institutional investors held Tandem Diabetes Care (TNDM) as of Q2 2016, down from 90 in Q1 2016.
- Funds reported $136M of Tandem Diabetes Care stock for Q2 2016, down 18% quarter-over-quarter.
- 10 funds opened new Tandem Diabetes Care positions in Q2 2016 and 20 closed out, a net change of -10 holders.
- The largest Tandem Diabetes Care buyer in Q2 2016 was Archon Capital Management, an estimated $2.41M added.
- The largest Tandem Diabetes Care seller in Q2 2016 was Sectoral Asset Management, an estimated $2.34M sold.
Based on aggregated 13F filings for Q2 2016.